

38th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Plenary Opening Session: Recent Advances and Emerging Opportunities in Medicinal Chemistry Sponsored by Gilead

Rediscovering Macrocycles as a Modality in Drug Discovery (PL02)



Dr Katerina LEFOTHERIS
(VILYA, INC., SF Bay Area, CA, United States)

A Synopsis of the Impact of Small Molecules on Human Health and Longevity (PL01)



Dr Nicholas MEANWELL
(BARUCH S. BLUMBERG INSTITUTE AND UNIVERSITY OF MICHIGAN, Wallingford, CT, United States)

Inhibition of Protein Aggregation and the Development of AKV9 (formerly NU-9) for Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases (PL03)



Prof. Richard B. SILVERMAN
(NORTHWESTERN UNIVERSITY, Evanston, IL, United States)

Session 1: Advances in Protein Proximity, Induction and Degradation

Magnet Biomedicine's TrueGlue Platform: A Systematic Approach Towards the Discovery of Molecular Glues for Therapeutic Intervention (IL06)



Dr Matthew HAYWARD
(MAGNET BIOMEDICINE, Boston, MA, United States)

Hold and Kill: RIPTAC™ Therapeutics Present a Novel Mechanism to Conquer Cancer (IL05)



Dr Kat KAYSER-BRICKER
(HALDA THERAPEUTICS, New Haven, CT, United States)

Stabilization of 14-3-3 Protein-Protein Interactions with Covalent Molecular Glues (IL04)



Dr Markella KONSTANTINIDOU
(UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, San Francisco, CA, United States)

Informatics Accelerated CRBN Glue Lead Discovery (IL02)



Dr Lingling SHEN
(NOVARTIS, Belmont, United States)

Design and Optimisation of Molecular Glue Degraders (IL03)



Dr Magnus WALTER
(MONTE ROSA THERAPEUTICS, Basel, Switzerland)

38th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Ubiquitin Ligases and Molecular Glue Degraders (IL01)



Prof. Ning ZHENG
(UNIVERSITY OF WASHINGTON, Seattle, WA, United States)

Session 2: Chemical Perturbation of Methylation towards Anticancer Drug Discovery

Development of Potent and Specific Inhibitors for Methyltransferases (IL08)



Prof. Rong HUANG
(PURDUE UNIVERSITY, West Lafayette, IN, United States)

Discovery of Novel Small-molecule Degraders for Protein Methyltransferases and Development of New Approaches to Target Undruggable Proteins (IL07)



Prof. Jian JIN
(ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, NY, United States)

Discovery of MRTX1719, a Synthetic Lethal Approach for the Treatment of MTAP-Deleted Cancers (IL09)



Dr Matthew MARX
(MIRATI THERAPEUTICS INC, San Diego, United States)

Session 3: Infectious Disease Drug Discovery

Targeting Infectious Diseases with Kinase Inhibitors (IL10)



Dr David DREWRY
(UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, NC, United States)

Development of Quinazolin-4-Ones that Show Efficacy in Lethal Murine Models of Venezuelan and Eastern Equine Encephalitis (IL11)



Dr Jennifer GOLDEN
(UNIVERSITY OF WISCONSIN, Madison, WI, United States)

Invention of MK-7602: an Antimalarial Drug Discovery Collaboration (IL12)



Dr John A. MCCAULEY
(MERCK, West Point, United States)

Session 4: Targeted Drug Delivery

Targeted Radionuclide Therapy: the Promise and Challenges of Short-lived Alpha-emitting Actinides (IL15)

38th ACS National Medicinal Chemistry Symposium

Confirmed Speakers



Dr Rebecca ABERGEL
(UNIVERSITY OF CALIFORNIA, Berkeley, CA, United States)

Development of a Novel TOPO1 α ADC Platform: from Concept to Pipeline Application (IL13)



Dr Mark PETERSEN
(ZYMEWORKS, Vancouver, Canada)

Harnessing the Power of ADCs by Careful Selection of Target, Linker, Payload, Indication, and Combination Partner (IL14)



Dr Sharsti SANDALL
(PFIZER, Bothell, WA, United States)

Session 5: Non-catalytic Kinase Function and Pseudokinases as Drug Targets

Targeting Functional Sites on Pseudokinase Complexes (IL16)



Dr Arvin DAR
(MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY, United States)

Discovery of the Tyk2 Pseudokinase Domain as a Drug Target (IL17)



Dr John TOKARSKI
(BRISTOL MYERS SQUIBB, Princeton, United States)

Discovery of TAK-279, a Highly Potent and Selective TYK2 Pseudokinase Inhibitor for the Treatment of Autoimmune Diseases, through Structure-based Drug Design (IL18)



Dr Angela TOMS WEST
(NIMBUS THERAPEUTICS, INC., Franklin, MA, United States)

Session 6: A Medicinal Chemist's Toolbox

Metabolism-Driven Drug Design: Role of Metabolite Profiling and Identification in Medicinal Chemistry (IL24)



Dr Deepak DALVIE
(CRINETICS PHARMACEUTICALS, San Diego, CA, United States)

Lessons in Proteome-Wide Covalent Drug Discovery (IL23)



Dr Benjamin HORNING
(VIVIDION THERAPEUTICS INC., San Diego, United States)

38th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Non-additivity in Drug Design (IL19)



Dr Bernd KUHN
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

The Rise of Targeting Chimeras (TACs): Next-generation Medicines that Preempt Cellular Events (IL20)



Dr Veerabahu SHANMUGASUNDARAM
(BRISTOL MYERS SQUIBB, Cambridge, MA, United States)

Kinetic Selectivity? A Missed Opportunity in Drug Discovery? (IL21)



Prof. Peter TONGE
(STONY BROOK UNIVERSITY, Stony Brook, NY, United States)

Mechanism-Based Approaches for Targeting Histone Reader Proteins (IL22)



Prof. Marcey WATERS
(UNIVERSITY OF NORTH CAROLINA, Chapel Hill, NC, United States)

Session 7: Use of Machine Learning in Drug Discovery

Machine Learning Guided Design of Peptide-based Antibiotics and Antivirals (IL25)



Dr Gaurav BHARDWAJ
(UNIVERSITY OF WASHINGTON, Seattle, WA, United States)

Rapid Identification of HPGD Inhibitors Using Physics-based Machine Learning Methods (IL28)



Dr Leela Sriram DODDA
(NIMBUS THERAPEUTICS, Boston, United States)

The Application of AI and ML to Small Molecule Drug Discovery (IL26)



Dr Gavin HIRST
(ATOMWISE, San Francisco, CA, United States)

Driving Innovation with Machine Learning: Impact on a Pipeline of Drug Discovery Programs (IL27)



Dr Jennifer KNIGHT
(SCHRÖDINGER, New York, NY, United States)

Applying Active Learning in Drug Discovery (IL29)

38th ACS National Medicinal Chemistry Symposium

Confirmed Speakers



Dr Patrick WALTERS
(RELAY THERAPEUTICS, Cambridge, MA, United States)

Generate-make-test: AI-in-the-loop High-throughput Drug Discovery (IL30)



Dr Matt WELBORN
(IAMBIC THERAPEUTICS, La Jolla, CA, United States)

MEDI Awards Session

Ralph F. Hirschmann Award Lecture

Rational Design of Protein-Protein Interaction Inhibitors: a Quixotic Quest (AL02)



Prof. Paramjit ARORA
(NYU, New York, United States)

MEDI Division Award Lecture

Unlocking Allostery for Drug Discovery (AL01)



Dr Maria-Jesus BLANCO
(ATAVISTIK BIO, Cambridge, MA, United States)